Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
clofarabine | ANDA | 2024-02-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Code | Description |
---|---|
J9027 | Injection, clofarabine, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 22 | 30 | 3 | — | — | 46 |
Myeloid leukemia acute | D015470 | — | C92.0 | 14 | 22 | 3 | — | — | 34 |
Myeloid leukemia | D007951 | — | C92 | 12 | 21 | 3 | — | — | 31 |
Myelodysplastic syndromes | D009190 | — | D46 | 10 | 15 | 1 | — | — | 22 |
Preleukemia | D011289 | — | — | 7 | 14 | 1 | — | — | 19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 11 | 8 | — | — | — | 15 |
Lymphoid leukemia | D007945 | — | C91 | 12 | 6 | — | — | — | 15 |
Syndrome | D013577 | — | — | 3 | 12 | — | — | — | 14 |
Neoplasms | D009369 | — | C80 | 6 | 1 | — | — | — | 6 |
Lymphoma | D008223 | — | C85.9 | 6 | 4 | — | — | — | 6 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 3 | 2 | — | — | — | 4 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 3 | 2 | — | — | — | 4 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 1 | — | — | — | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 3 | — | — | — | 4 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 2 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | — | — | — | — | 1 |
Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Clofarabine |
INN | clofarabine |
Description | Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. |
Classification | Small molecule |
Drug class | antineoplastics (arabinofuranosyl derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
PDB | — |
CAS-ID | 123318-82-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1750 |
ChEBI ID | 681569 |
PubChem CID | 119182 |
DrugBank | DB00631 |
UNII ID | 762RDY0Y2H (ChemIDplus, GSRS) |